logo
logo
AI Products 
Leaderboard Community🔥 Earn points

Cancer Biomarkers Market Set to Achieve USD 42.0 Billion by 2029, Growing at 11.3% CAGR

avatar
Markets and Markets
collect
0
collect
0
collect
0
Cancer Biomarkers Market Set to Achieve USD 42.0 Billion by 2029, Growing at 11.3% CAGR

The Cancer Biomarkers Market Forecast estimates growth from USD 24.5 billion in 2024 to USD 42.0 billion by 2029, at a CAGR of 11.3%. Factors contributing to this growth include the rising cancer incidence, growing awareness about early diagnosis, substantial investments in cancer biomarker research, and the biomarkers' vital role in diagnosis, drug discovery, and development. Additionally, emerging markets like China, Japan, and India offer promising growth opportunities for companies.


Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202


Omics Technology Leads Cancer Biomarkers Market by Profiling Method


The cancer biomarkers market is segmented based on profiling methods into omics technologies and imaging technologies. In 2023, the omics technology segment held the largest market share, driven by its high-throughput capabilities in cancer biomarker discovery and diagnosis.


Breast Cancer Segment Poised for Rapid Growth


The market is further categorized by cancer type, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancers. In 2023, the breast cancer segment dominated the market, largely due to the rising global incidence of breast cancer and heightened awareness for early diagnosis, prevention, and treatment.


Instruments Segment Dominates by Product


Based on product type, the cancer biomarkers market is divided into instruments, consumables, and bioinformatics software. The instruments segment held the largest share in 2023, owing to the continuous demand for cancer detection, advancements in instrument technology, and the high accuracy of detection methods.


Diagnostics Segment Leads by Application


The cancer biomarkers market is also segmented by application into risk assessment, prognostics, diagnostics, and research & development. In 2023, the diagnostics segment led the market, driven by the rising incidence of cancer, increasing awareness and acceptance of diagnostic tests, and the introduction of technologically advanced biomarker products.


North America Holds Largest Market Share


Regionally, the global cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America emerged as the largest market in 2023, attributed to the growing prevalence of cancer, increasing research activities, technological advancements, and the expanding use of cancer biomarkers in drug discovery and development.


Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202


Key Market Players


Leading companies in the cancer biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), and Centogene N.V. (Germany).


Related News & Articles


https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp


https://www.marketsandmarkets.com/ResearchInsight/oncology-biomarkers.asp


https://www.prnewswire.com/news-releases/cancer-biomarkers-market-worth-42-0-billion--marketsandmarkets-302129875.html


https://finance.yahoo.com/news/cancer-biomarkers-market-expected-reach-123000501.html



Contact:


Mr. Aashish Mehra


MarketsandMarkets™ INC.


630 Dundee Road


Suite 430


Northbrook, IL 60062


USA : 1-888-600-6441


sales@marketsandmarkets.com

collect
0
collect
0
collect
0
avatar
Markets and Markets